BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas

Matteo Martinoni, Gianluca Marucci, Dario De Biase, Guido Rubboli, Lilia Volpi, Patrizia Riguzzi, Federica Marliani, Francesco Toni, Ilaria Naldi, Francesca Bisulli, Paolo Tinuper, Roberto Michelucci, Agostino Baruzzi, Giovanni Tallini, Marco Giulioni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of this study was to verify the presence of BRAF mutations in a series of six patients affected by drug-resistant focal epilepsy associated with neocortical posterior temporal gangliogliomas (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of epilepsy and represent the most common tumor in young patients undergoing surgery for intractable focal epilepsy. BRAF mutations have been identified in up to 50% of GG. Interestingly, these six patients shared a specific anatomical posterior temporal site. In all patients, histological examination confirmed the diagnosis of GG, and two were also associated with a focal cortical dysplasia (FCD) type IIa. BRAF mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of Patient 2 showed a concomitant BRAF V600E mutation. All patients but one (83.3%) achieved Engel Class Ia seizure control. The patient carrying a concomitant BRAF mutation in GG and FCD fell into Engel Class II. Further analyses will be required in order to better understand the meaning of BRAF mutations in epilepsy-associated tumors and FCD and their possible role as a prognostic seizure outcome and tumor behavior marker.

Original languageEnglish
Pages (from-to)1250-1253
Number of pages4
JournalJournal of Clinical Neuroscience
Volume22
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Ganglioglioma
Mutation
Malformations of Cortical Development
Partial Epilepsy
Epilepsy
Seizures
Tumor Biomarkers
Neoplasms

Keywords

  • BRAF V600E mutation
  • Epilepsy surgery
  • Focal cortical dysplasia
  • Gangliogliomas
  • Pharmacoresistant epilepsy
  • Seizure outcome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)
  • Medicine(all)

Cite this

BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas. / Martinoni, Matteo; Marucci, Gianluca; De Biase, Dario; Rubboli, Guido; Volpi, Lilia; Riguzzi, Patrizia; Marliani, Federica; Toni, Francesco; Naldi, Ilaria; Bisulli, Francesca; Tinuper, Paolo; Michelucci, Roberto; Baruzzi, Agostino; Tallini, Giovanni; Giulioni, Marco.

In: Journal of Clinical Neuroscience, Vol. 22, No. 8, 01.08.2015, p. 1250-1253.

Research output: Contribution to journalArticle

Martinoni, Matteo ; Marucci, Gianluca ; De Biase, Dario ; Rubboli, Guido ; Volpi, Lilia ; Riguzzi, Patrizia ; Marliani, Federica ; Toni, Francesco ; Naldi, Ilaria ; Bisulli, Francesca ; Tinuper, Paolo ; Michelucci, Roberto ; Baruzzi, Agostino ; Tallini, Giovanni ; Giulioni, Marco. / BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas. In: Journal of Clinical Neuroscience. 2015 ; Vol. 22, No. 8. pp. 1250-1253.
@article{b3f7d57805d24e9486dcaca7c9ba8853,
title = "BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas",
abstract = "The aim of this study was to verify the presence of BRAF mutations in a series of six patients affected by drug-resistant focal epilepsy associated with neocortical posterior temporal gangliogliomas (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of epilepsy and represent the most common tumor in young patients undergoing surgery for intractable focal epilepsy. BRAF mutations have been identified in up to 50{\%} of GG. Interestingly, these six patients shared a specific anatomical posterior temporal site. In all patients, histological examination confirmed the diagnosis of GG, and two were also associated with a focal cortical dysplasia (FCD) type IIa. BRAF mutations were found in four out of six GG (66.6{\%}). Furthermore, dysplastic tissue of Patient 2 showed a concomitant BRAF V600E mutation. All patients but one (83.3{\%}) achieved Engel Class Ia seizure control. The patient carrying a concomitant BRAF mutation in GG and FCD fell into Engel Class II. Further analyses will be required in order to better understand the meaning of BRAF mutations in epilepsy-associated tumors and FCD and their possible role as a prognostic seizure outcome and tumor behavior marker.",
keywords = "BRAF V600E mutation, Epilepsy surgery, Focal cortical dysplasia, Gangliogliomas, Pharmacoresistant epilepsy, Seizure outcome",
author = "Matteo Martinoni and Gianluca Marucci and {De Biase}, Dario and Guido Rubboli and Lilia Volpi and Patrizia Riguzzi and Federica Marliani and Francesco Toni and Ilaria Naldi and Francesca Bisulli and Paolo Tinuper and Roberto Michelucci and Agostino Baruzzi and Giovanni Tallini and Marco Giulioni",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.jocn.2015.02.016",
language = "English",
volume = "22",
pages = "1250--1253",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "8",

}

TY - JOUR

T1 - BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas

AU - Martinoni, Matteo

AU - Marucci, Gianluca

AU - De Biase, Dario

AU - Rubboli, Guido

AU - Volpi, Lilia

AU - Riguzzi, Patrizia

AU - Marliani, Federica

AU - Toni, Francesco

AU - Naldi, Ilaria

AU - Bisulli, Francesca

AU - Tinuper, Paolo

AU - Michelucci, Roberto

AU - Baruzzi, Agostino

AU - Tallini, Giovanni

AU - Giulioni, Marco

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The aim of this study was to verify the presence of BRAF mutations in a series of six patients affected by drug-resistant focal epilepsy associated with neocortical posterior temporal gangliogliomas (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of epilepsy and represent the most common tumor in young patients undergoing surgery for intractable focal epilepsy. BRAF mutations have been identified in up to 50% of GG. Interestingly, these six patients shared a specific anatomical posterior temporal site. In all patients, histological examination confirmed the diagnosis of GG, and two were also associated with a focal cortical dysplasia (FCD) type IIa. BRAF mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of Patient 2 showed a concomitant BRAF V600E mutation. All patients but one (83.3%) achieved Engel Class Ia seizure control. The patient carrying a concomitant BRAF mutation in GG and FCD fell into Engel Class II. Further analyses will be required in order to better understand the meaning of BRAF mutations in epilepsy-associated tumors and FCD and their possible role as a prognostic seizure outcome and tumor behavior marker.

AB - The aim of this study was to verify the presence of BRAF mutations in a series of six patients affected by drug-resistant focal epilepsy associated with neocortical posterior temporal gangliogliomas (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of epilepsy and represent the most common tumor in young patients undergoing surgery for intractable focal epilepsy. BRAF mutations have been identified in up to 50% of GG. Interestingly, these six patients shared a specific anatomical posterior temporal site. In all patients, histological examination confirmed the diagnosis of GG, and two were also associated with a focal cortical dysplasia (FCD) type IIa. BRAF mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of Patient 2 showed a concomitant BRAF V600E mutation. All patients but one (83.3%) achieved Engel Class Ia seizure control. The patient carrying a concomitant BRAF mutation in GG and FCD fell into Engel Class II. Further analyses will be required in order to better understand the meaning of BRAF mutations in epilepsy-associated tumors and FCD and their possible role as a prognostic seizure outcome and tumor behavior marker.

KW - BRAF V600E mutation

KW - Epilepsy surgery

KW - Focal cortical dysplasia

KW - Gangliogliomas

KW - Pharmacoresistant epilepsy

KW - Seizure outcome

UR - http://www.scopus.com/inward/record.url?scp=84937518136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937518136&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2015.02.016

DO - 10.1016/j.jocn.2015.02.016

M3 - Article

C2 - 25937573

AN - SCOPUS:84937518136

VL - 22

SP - 1250

EP - 1253

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 8

ER -